290 related articles for article (PubMed ID: 18391758)
1. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.
von Euler H; Sadeghi A; Carlsson B; Rivera P; Loskog A; Segall T; Korsgren O; Tötterman TH
J Immunother; 2008 May; 31(4):377-84. PubMed ID: 18391758
[TBL] [Abstract][Full Text] [Related]
2. Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma.
Westberg S; Sadeghi A; Svensson E; Segall T; Dimopoulou M; Korsgren O; Hemminki A; Loskog AS; Tötterman TH; von Euler H
J Immunother; 2013; 36(6):350-8. PubMed ID: 23799414
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
4. AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.
Malmström PU; Loskog AS; Lindqvist CA; Mangsbo SM; Fransson M; Wanders A; Gårdmark T; Tötterman TH
Clin Cancer Res; 2010 Jun; 16(12):3279-87. PubMed ID: 20448220
[TBL] [Abstract][Full Text] [Related]
5. Pulse-mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma.
Spugnini EP; Dragonetti E; Vincenzi B; Onori N; Citro G; Baldi A
Melanoma Res; 2006 Feb; 16(1):23-7. PubMed ID: 16432452
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen.
Gyorffy S; Rodriguez-Lecompte JC; Woods JP; Foley R; Kruth S; Liaw PC; Gauldie J
J Vet Intern Med; 2005; 19(1):56-63. PubMed ID: 15715049
[TBL] [Abstract][Full Text] [Related]
7. Canine oral melanoma.
Bergman PJ
Clin Tech Small Anim Pract; 2007 May; 22(2):55-60. PubMed ID: 17591290
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy of oral malignant melanomas in dogs.
Blackwood L; Dobson JM
J Am Vet Med Assoc; 1996 Jul; 209(1):98-102. PubMed ID: 8926220
[TBL] [Abstract][Full Text] [Related]
9. Relationship between regulatory and type 1 T cells in dogs with oral malignant melanoma.
Horiuchi Y; Tominaga M; Ichikawa M; Yamashita M; Okano K; Jikumaru Y; Nariai Y; Nakajima Y; Kuwabara M; Yukawa M
Microbiol Immunol; 2010 Mar; 54(3):152-9. PubMed ID: 20236425
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up.
Saellstrom S; Sadeghi A; Eriksson E; Segall T; Dimopoulou M; Korsgren O; Loskog AS; Tötterman TH; Hemminki A; Ronnberg H
Front Vet Sci; 2021; 8():695222. PubMed ID: 34368282
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunology and canine malignant melanoma: A comparative review.
Atherton MJ; Morris JS; McDermott MR; Lichty BD
Vet Immunol Immunopathol; 2016 Jan; 169():15-26. PubMed ID: 26827834
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
Bergman PJ; McKnight J; Novosad A; Charney S; Farrelly J; Craft D; Wulderk M; Jeffers Y; Sadelain M; Hohenhaus AE; Segal N; Gregor P; Engelhorn M; Riviere I; Houghton AN; Wolchok JD
Clin Cancer Res; 2003 Apr; 9(4):1284-90. PubMed ID: 12684396
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients.
Schiza A; Wenthe J; Mangsbo S; Eriksson E; Nilsson A; Tötterman TH; Loskog A; Ullenhag G
J Transl Med; 2017 Apr; 15(1):79. PubMed ID: 28427434
[TBL] [Abstract][Full Text] [Related]
14. Canine limbal melanoma: 30 cases (1992-2004). Part 1. Signalment, clinical and histological features and pedigree analysis.
Donaldson D; Sansom J; Scase T; Adams V; Mellersh C
Vet Ophthalmol; 2006; 9(2):115-9. PubMed ID: 16497236
[TBL] [Abstract][Full Text] [Related]
15. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours.
Pires I; Garcia A; Prada J; Queiroga FL
J Comp Pathol; 2010; 143(2-3):142-9. PubMed ID: 20207364
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical characterization and evaluation of prognostic factors in canine oral melanomas with osteocartilaginous differentiation.
Sánchez J; Ramirez GA; Buendia AJ; Vilafranca M; Martinez CM; Altimira J; Navarro JA
Vet Pathol; 2007 Sep; 44(5):676-82. PubMed ID: 17846240
[TBL] [Abstract][Full Text] [Related]
17. Enhancing antimelanoma immune responses through apoptosis.
Bianco SR; Sun J; Fosmire SP; Hance K; Padilla ML; Ritt MG; Getzy DM; Duke RC; Withrow SJ; Lana S; Matthiesen DT; Dow SW; Bellgrau D; Cutter GR; Helfand SC; Modiano JF
Cancer Gene Ther; 2003 Sep; 10(9):726-36. PubMed ID: 12944992
[TBL] [Abstract][Full Text] [Related]
18. Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival.
Brockley LK; Cooper MA; Bennett PF
N Z Vet J; 2013 Jan; 61(1):25-31. PubMed ID: 22913610
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2.
Quintin-Colonna F; Devauchelle P; Fradelizi D; Mourot B; Faure T; Kourilsky P; Roth C; Mehtali M
Gene Ther; 1996 Dec; 3(12):1104-12. PubMed ID: 8986437
[TBL] [Abstract][Full Text] [Related]
20. [Combined use of irradiation and DNA tumor vaccine to treat canine oral malignant melanoma: a pilot study].
Herzog A; Buchholz J; Ruess-Melzer K; Lang J; Kaser-Hotz B
Schweiz Arch Tierheilkd; 2013 Feb; 155(2):135-42. PubMed ID: 23385072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
